Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.
TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
MimiVax, LLC is a clinical-stage biotechnology company based in Buffalo, New York, focused on developing immunotherapeutic vaccines and targeted therapies for cancer treatment. Founded in 2011, the company specializes in creating vaccines that utilize survivin-targeting technology, which aims to disrupt a cell-survival protein commonly found in various cancers. Its lead product, SurVaxM, is a peptide mimic immunotherapeutic vaccine designed to control tumor growth and recurrence, enhancing the potential for patient survival. Through its innovative approach, MimiVax seeks to provide healthcare providers with effective tools to improve cancer treatment outcomes.
Modifi Biosciences is a leader in direct DNA modification and the development of novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drug development methods.
Kiyatec, LLC is a biotechnology company based in Greenville, South Carolina, specializing in the development of advanced 3D cell-based assays for preclinical drug discovery and clinical therapy applications. The company utilizes patients' own living tumor cells to create functional 3D models that facilitate testing of various cancer therapies, enhancing the predictive accuracy of drug responses. Its innovative 3DKUBE technology platform supports in situ imaging and accommodates different scaffold materials, allowing for the modeling of complex human biology through segregated cell co-culture. Kiyatec's services include drug response profiling, toxicity evaluation, and the development of cell-based models for testing small molecules, biologic drugs, and immunotherapies. The company also engages in contract research projects and collaborates with the National Cancer Institute to advance research on cancer types such as breast cancer, glioblastoma, and lung cancer. Founded in 2005, Kiyatec aims to assist medical practitioners in identifying effective treatments for cancer patients by providing insights prior to clinical trials.
AiM Medical Robotics developing a robotic system for use in neurosurgical procedures. The system is unique in that it is MRI compatible, allowing patients to be treated while in the MRI scanner. This gives physicians the ability to capture real-time imaging feedback to improve outcomes. Its system will help treat patients with Parkinson's, Epilepsy, Tremors, and brain cancer.
Agrivida, Inc. is an animal health and nutrition company that specializes in developing feed additives for various livestock, including poultry, swine, dairy, beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida focuses on innovative enzyme solutions to enhance animal nutrition. Its flagship product, GRAINZYME, utilizes advanced technology to produce beneficial enzymes such as phytase and glucanase within corn kernels. This approach allows for a natural and efficient means of integrating these enzymes into animal diets, promoting healthier livestock while also reducing environmental impact. Agrivida's mission is to provide effective nutrition solutions that support sustainable food production across the agriculture sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.